SLXN
Silexion Therapeutics Ltd.
There isn't enough reported data to score SLXN yet.
SLXN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate SLXN's fundamentals.
SLXN PE Valuation
SLXN has no meaningful PE right now: it lost money over the past year.
SLXN Forward outlook
There aren't enough analyst estimates for SLXN to show an outlook.
SLXN Earnings Per Share
SLXN Quarterly Revenue
SLXN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.2M | +$690K |
| Q2 2026 | -$2.9M | -$417K |
| Q1 2026 | -$3.6M | -$1.2M |
| Q4 2025 | -$3M | -$92K |
| Q3 2025 | -$2.8M | -$174K |
SLXN has burned cash in almost every quarter: −$12M over the past year, against −$11M the year before.
SLXN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +113% | +15.2K shares |
| 1 year | +1421% | +26.8K shares |
SLXN has 28,640 diluted shares, up 1421% from a year ago.
SLXN Net Leverage
SLXN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SLXN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 17.4 | Oversold |
| Stochastic | 0.2 | Oversold |
SLXN's weekly RSI is 17 (oversold) and its Stochastic is 0 (oversold).
SLXN PE vs Healthcare Sector
SLXN has no meaningful PE right now: it lost money over the past year.
SLXN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.43 | 40% below |
| 20 week MA | $21.2 | 87% below |
| 50 week MA | $204.8 | 99% below |
| 100 week MA | $1,619.4 | 100% below |
SLXN is in a downtrend: it's below all four of its weekly moving averages, and 100% below its 100-week average.
SLXN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $63,180.0 | $7,560.0 | -88% |
| 2025 | $7,560.0 | $549.6 | -93% |
| 2026 YTD | $549.6 | $2.66 | -100% |
SLXN has finished every year since 2024 lower, and it's down 100% so far in 2026.